Questions answered
Ipamorelin: Frequently Asked Questions
Direct answers to the regulatory, safety, and research questions people actually ask about ipamorelin — each cited to the record.
Is ipamorelin FDA approved?
No. Ipamorelin has never been approved by the FDA, or any other regulator, for any indication [3]. Its only published human trial — for postoperative ileus — missed its primary endpoint [3]. In 2024 the FDA also removed ipamorelin acetate from the Section 503A bulk-substances list, so it is not an approved substance for compounding either [3].
Is ipamorelin legal?
Ipamorelin is sold as a research chemical, not an approved medicine, and has no approved human use [3]. It is prohibited in sport at all times under WADA category S2 [7]. Its 2024 removal from the FDA's 503A bulk list narrowed legitimate compounding access [3]. Legal status varies by jurisdiction and use; this is an editorial summary, not legal advice.
Is ipamorelin banned by WADA?
Yes. Ipamorelin is prohibited at all times under the World Anti-Doping Agency Prohibited List, category S2 (peptide hormones, growth factors, and mimetics), as a growth hormone secretagogue [7]. Accredited laboratories detect it in urine using validated mass-spectrometry methods at sub-nanogram-per-millilitre limits [7][8][9].
Why did the FDA restrict ipamorelin compounding?
In 2024, following the nominator's withdrawal in September, the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list, and both the acetate and free base were reviewed at the October 29, 2024 PCAC meeting [3]. The result is that ipamorelin is not an approved bulk substance for compounding [3].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively releases growth hormone by activating the ghrelin receptor (GHS-R1a) on the pituitary [1]. Its founding characterization showed potent GH release in rats and pigs (pig effective dose 2.3 nmol/kg) without raising cortisol — the first highly GH-selective secretagogue [1].
What does ipamorelin do for you?
In studies, ipamorelin triggers a single pulse of growth hormone via the ghrelin receptor, without the cortisol rise older peptides caused [1]. In humans it produces a GH pulse peaking around 40 minutes after dosing [2]. Beyond that mechanism, no controlled human trial has shown an outcome benefit; its one efficacy trial failed [3].
What is ipamorelin peptide?
Ipamorelin peptide is a five-amino-acid (pentapeptide) growth hormone secretagogue, wholly synthetic, that mimics the body's ghrelin at the GHS-R1a receptor to release GH [1]. It is not an endogenous human peptide; it was derived from GHRP-1 by removing a central dipeptide, and its non-natural building blocks resist enzymatic breakdown [1].
What are the risks of ipamorelin?
The honest answer is that long-term human risk is uncharacterized — the only controlled human trial ran up to 7 days [3]. Mechanistic cautions exist around cancer (GH/IGF-1 signaling), blood sugar, the heart (a related compound caused myocardial damage in rats [6]), and appetite. Research-grade material is also of unverified purity [2]. See the effects page for the cited detail.
Does ipamorelin reduce belly fat?
No human trial demonstrates ipamorelin reduces belly fat. In a 2024 ferret study, ipamorelin (1–3 mg/kg intraperitoneal) blunted chemotherapy-induced weight loss by about 24%, a weight-protection effect rather than fat loss [5]. Community reports of gradual leaning-out are anecdotal and confounded by diet and training, not a proven ipamorelin effect.
What are the downsides of ipamorelin?
The central downside is that efficacy has never been demonstrated in a successful human trial — the one published trial failed [3]. Add an absence of long-term safety data, a class-level heart signal from a related agonist [6], appetite stimulation via the ghrelin receptor, and unregulated supply quality [2]. Community-reported side effects include flushing, tingling, and water retention.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue. Its clinical development effectively stopped after the Phase 2 postoperative-ileus trial missed its endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the 503A bulk-substances list, restricting compounding-pharmacy access — which is the "going away" some readers have in mind [3].
What does CJC-1295 and ipamorelin do?
The combination pairs ipamorelin (a ghrelin-receptor GH-releasing peptide) with CJC-1295 (a GHRH analog) to push GH release through two complementary receptor pathways [1]. No controlled trial has tested the pair for any outcome [3]. A 2020 andrology review discusses such growth-hormone-secretagogue use against the absence of approved indications [10].
Does ipamorelin increase IGF-1?
Growth hormone drives hepatic IGF-1, so sustained GH elevation can raise IGF-1 — but in short rodent ipamorelin studies, IGF-1 was not consistently elevated. The rat bone-growth study found dose-dependent bone growth with no measurable change in total IGF-1, suggesting a partly local, GH-pulse-driven effect [4]. The IGF-1 response appears context- and duration-dependent.
How does CJC-1295 ipamorelin work?
Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells to release a GH pulse [1]; CJC-1295, a GHRH analog, works through the separate GHRH receptor. Combining them engages two different pathways toward the same outcome — GH release [1]. The combination's real-world claims rest on single-agent pharmacology, not combination trials [3].
How much CJC-1295 ipamorelin should I take?
This site does not provide a dose. There is no approved or trial-validated human dose for ipamorelin or the CJC-1295 plus ipamorelin combination [3]. Online "stack" protocols have no peer-reviewed human dosing basis and are anecdotal, not recommendations [3]. The 2020 andrology review frames the gap between marketed use and approved indications for this class [10].
Does CJC-1295 ipamorelin work?
No controlled human trial has tested the CJC-1295 plus ipamorelin combination for any endpoint, so there is no trial-grade evidence it works [3]. Ipamorelin alone reliably releases a GH pulse in humans [2], but that is a mechanism, not an outcome. The popular efficacy claims are extrapolations from single-compound data [10].
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is typically refrigerated [2]. These are general peptide-handling notes from the research-supply literature, not a preparation instruction — this site gives no volumes or concentrations for human use.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg [2]. The GH pulse it triggers peaks around 40 minutes post-dose [2]. For anti-doping purposes, accredited labs can still detect ipamorelin and its metabolites in urine at sub-nanogram levels well after dosing [9].
Does ipamorelin make you hungry?
Some users report increased appetite, and there is a mechanistic basis: ipamorelin activates the ghrelin receptor — the same target the body's hunger hormone uses — and ghrelin-receptor agonists activate brain appetite centers and induce feeding in animals [18]. Community accounts describe it as milder than GHRP-6. It is reported anecdotally, not confirmed as a human finding.
Will I gain weight on ipamorelin?
No human trial answers this directly. In mice, ipamorelin showed GH-independent stimulation of fat gain over two weeks [17], and in ferrets it protected against chemotherapy weight loss [5]. The failed human trial was short-term and did not assess body composition as an outcome [3]. Community reports vary and are confounded by diet and training.
Does ipamorelin increase appetite?
Mechanistically it can: ipamorelin acts on the ghrelin (GHS-R1a) receptor, and ghrelin-receptor agonists activate hypothalamic appetite centers and induce feeding in animal studies [18]. Community reports describe an appetite uptick in the hours after injection, generally milder than with GHRP-6. This is consistent with the mechanism but is reported anecdotally for ipamorelin, not confirmed in a human trial.
What does ipamorelin peptide do?
Ipamorelin peptide selectively releases growth hormone by activating the pituitary ghrelin receptor, producing a discrete GH pulse without raising cortisol or prolactin [1]. In humans that pulse peaks around 40 minutes after dosing [2]. Outside that mechanism, no successful human outcome trial exists — its single efficacy trial failed its endpoint [3].